Lupus Anticoagulants

It is a diverse family of immunoglobulins known as lupus anticoagulants target the epitopes of prothrombin, beta2-glycoprotein I (beta2-GPI), and the negatively charged phospholipid binding protein of cell membranes, which together impede phospholipid-dependent coagulation in vitro. Ironically, LA is linked to venous and arterial thrombosis rather than bleeding. Comparing LA’s thrombogenic risk to that of anti-beta-glycoprotein I or anticardiolipin antibodies, LA is thought to be the biggest risk factor. Furthermore, beta2-glycoprotein I (beta2-GPI) autoantibodies correlate more strongly with the risk of thrombosis than antiprothrombin autoantibodies. These immunoglobins may spontaneously form due to drugs, infections, or autoimmune disorders like lupus erythematosus. The probability of develo** acquired lupus anticoagulant is increased by infections such as EBV, syphilis, and hepatitis C. Acquired hypoprothrombinemia, lupus anticoagulant, and often moderate thrombocytopenia or...